IMPROVED BURN THERAPY THROUGH THE REGULATION OF INFLAMMATION

通过调节炎症改善烧伤治疗

基本信息

  • 批准号:
    5212043
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

Our central hypothesis is that burn injury may result in the activation of inflammatory mechanisms and the generation of dysfunctional levels of potent mediators. In effect, an "escape from control". These mediators in turn lead to a prolonged, intensive inflammatory/hypermetabolic response, providing a self-destructive process which adds to the physical injury of the burn. We have approached burn injury as the ultimate form of "inflammatory disease". Our initial studies focused on the role of complement activation as a major pathophysiologic component of burn injury. We found that, in patients, animals and in vitro, thermal injury activated complement, generating the anaphylatoxins C5a and C3a. More recently, our efforts turned to the role of cytokines in burn injury, sepsis, and shock. We now believe there is a major link between complement activation and cytokine generation and regulation. Thus, to design therapies to ensure a optimal host response to burn injury, we propose to study various factors involved in the stimulation, regulation, and inhibition of mediators involved in burn injury, drawing on our own expertise to focus on the proinflammatory cytokines and complement. Our specific aims are to: 1) characterize the precise structure-functional relationships whereby C5a stimulates cytokinemia. We have evidence to suggest that, by understanding precisely how C5a stimulates cytokine transcription and translation, we may intervene, therapeutically in this process; 2) study cytokine stimulation by activated platelets, again with an eye towards therapy; 3) better understand the recently documented differences in initial cytokine production in pure burn injury and in endotoxemia and Gram-positive infection. We specifically believe injury "primes" cells early in injury to produce proinflammatory cytokines and that they later become "hyposensitized", adding to immune dysregulation; 4) characterize specific organ cytokine production and related dysfunction; 5) further localize this to the cellular level; 6) characterize the regulation of cytokine responses of PBMCs in burn patients and correlate these with clinical parameters; 7) study expression of IL-1 receptors by cells of burn patients, as compared to normals; 8) develop a model in rats to study specific cytokine inhibitors in burns; 9) study endogenous IL-l receptor antagonist and TNF-binding protein in burn patients and normals, to define the response and establish levels necessary for therapy; 10) determine anaphylatoxin (C3a, C5a) control of IL-1 receptor antagonist, TNF-binding protein, or the inhibitory cytokine IL-10. The intent of all of these is ultimately to better regulate the inflammatory response to the benefit of the burn patient.
我们的中心假设是烧伤可能导致 炎症机制和功能障碍水平的产生 强有力的调解人。实际上,这是一种“逃离控制”。这些调解人 进而导致长期、强烈的炎症/高代谢 响应,提供了一个自我毁灭的过程,这增加了物理 烧伤造成的伤害。我们已经将烧伤作为终极形式 “炎症性疾病”。我们最初的研究集中在 补体激活是烧伤的主要病理生理成分 受伤。我们发现,在患者、动物和体外,热损伤 激活补体,产生过敏毒素C5a和C3a。更多 最近,我们的努力转向细胞因子在烧伤中的作用, 败血症和休克。我们现在相信, 补体激活和细胞因子的产生和调节。因此,要 设计治疗方法以确保对烧伤的最佳宿主反应,我们 建议研究涉及刺激、调节、 以及抑制参与烧伤损伤的介体,依靠我们自己 专注于促炎细胞因子和补体的专业知识。我们的 具体目标是:1)表征精确的结构-功能 C5a刺激细胞分裂素血症的关系。我们有证据证明 建议,通过准确了解C5a是如何刺激细胞因子的 转录和翻译,我们可能会介入,在治疗方面 过程;2)研究激活的血小板对细胞因子的刺激,再次使用 着眼于治疗;3)更好地理解最近记录的 单纯烧伤与烧伤患者初始细胞因子产生的差异 内毒素血症与革兰氏阳性感染。我们特别认为受伤 “启动”细胞在损伤早期产生促炎细胞因子和 它们后来变得“低敏”,加剧了免疫失调; 4)表征特定器官细胞因子的产生和相关 功能障碍;5)进一步定位于细胞水平;6) 烧伤时外周血单核细胞细胞因子反应的调控特征 患者及其与临床参数的相关性;7)研究 烧伤患者细胞IL-1受体表达的比较 正常;8)建立大鼠模型以研究特定的细胞因子抑制物 内源性IL-L受体拮抗剂与肿瘤坏死因子结合的研究 蛋白质在烧伤患者和正常人中的表达,以确定反应和 建立治疗所需的水平;10)测定过敏毒素(C3a, C5a)控制IL-1受体拮抗剂、肿瘤坏死因子结合蛋白或 抑制性细胞因子IL-10。所有这些措施的最终目的是 更好地调节炎症反应,有利于烧伤 有耐心的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFREY A GELFAND其他文献

JEFFREY A GELFAND的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFREY A GELFAND', 18)}}的其他基金

BABESIOSIS AS A PARADIGM FOR THE EFFECTS OF AGING
巴贝斯虫病作为衰老影响的一个范例
  • 批准号:
    6129303
  • 财政年份:
    2000
  • 资助金额:
    --
  • 项目类别:
IMPROVED BURN THERAPY THROUGH THE REGULATION OF INFLAMMATION
通过调节炎症改善烧伤治疗
  • 批准号:
    6240397
  • 财政年份:
    1996
  • 资助金额:
    --
  • 项目类别:
PATHOBIOLOGY OF INTRAVENOUS LIPID EMULSIONS IN CHILDREN
儿童静脉注射脂质乳剂的病理学
  • 批准号:
    3317108
  • 财政年份:
    1986
  • 资助金额:
    --
  • 项目类别:
PATHOBIOLOGY OF INTRAVENOUS LIPID EMULSIONS IN CHILDREN
儿童静脉注射脂质乳剂的病理学
  • 批准号:
    3317107
  • 财政年份:
    1984
  • 资助金额:
    --
  • 项目类别:
PATHOBIOLOGY OF INTRAVENOUS LIPID EMULSIONS IN CHILDREN
儿童静脉注射脂质乳剂的病理学
  • 批准号:
    3317106
  • 财政年份:
    1984
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Development of B cell functional studies on primary antibody deficiencies
一抗缺陷 B 细胞功能研究的进展
  • 批准号:
    502607
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
  • 批准号:
    502578
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
  • 批准号:
    MR/Y008847/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Enabling The Targeted Delivery Of DNA G-quadruplex Ligands using a Novel Antibody DAR-1 Platform
使用新型抗体 DAR-1 平台实现 DNA G 四链体配体的靶向递送
  • 批准号:
    BB/Y002180/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
  • 批准号:
    EP/Y024540/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Semi-Automated Antibody-Discovery Platform to Target Challenging Biomolecules
针对具有挑战性的生物分子的半自动化抗体发现平台
  • 批准号:
    MR/Y003616/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Monitoring antibody protection against SARS-CoV-2 variants
监测抗体对 SARS-CoV-2 变体的保护作用
  • 批准号:
    MR/Y033698/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Pharmacokinetic analysis of antibody drug conjugate in tumor cells utilizing synchrotron soft X-ray imaging
利用同步加速器软 X 射线成像对肿瘤细胞中抗体药物偶联物进行药代动力学分析
  • 批准号:
    23H03716
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了